Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
8 September 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. * (復星萬邦（江蘇）醫藥集團有限公司,"**Fosun Wanbang**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*(上海復星醫藥（集團）股份有限公司) (the "**Company**"), recently received the approval from the National Medical Products Administration(the "**NMPA**") for the clinical trial of Foritinib Succinate Capsules (project code: SAF-189; registration category of application: class 1 chemical medicine; hereinafter the "**New Drug**") for the adjuvant treatment following radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer(NSCLC) with anaplastic lymphoma kinase (ALK)-positive or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)-positive status. Fosun Wanbang intends to commence the Phase III clinical trial of the new drug in China (excluding Hong Kong, Macau and Taiwan, the same applies below) when the conditions are fulfilled.

II.Basic Information and Research Progress of the New Drug

The New Drug is an innovative small molecule chemical drug and is intended to be used primarily for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+), etc. The New Drug is subject to joint pre-clinical studies by Chongqing Fochon Pharmaceuticals, Ltd.* (重慶復創醫藥研究有限公司), a subsidiary

of the Company, and Shanghai Institute of Materia Medica Chinese Academy of Sciences, and Fosun Wanbang was granted the exclusive rights to develop (including but not limited to clinical trials and registration) and commercialize the New Drug in China (excluding Hong Kong, Macau and Taiwan, the same applies below). As shown by clinical studies to date, the New Drug has demonstrated good clinical efficacy in patients with advanced ALK-positive non-small cell lung cancer, with significant efficacy in central nervous system metastases and a good safety profile.

As of the date of this announcement (i.e.,8 September 2025), the drug registration applications of the New Drug for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), have been accepted by the NMPA. The phase II clinical study of another indication of the New Drug for the treatment of non-small cell lung cancer (ROS1+) had been completed in China.

As of July 2025, the Group (i.e., the Company and its subsidiaries/units) has invested approximately RMB453 million (unaudited) in total in the research and development (the "**R&D**") of the New Drug at current stage.

According to the latest data from IQVIA CHPA[1], in 2024, the sales of major drugs for the treatment of non-small cell lung cancer (ALK+) in China was approximately RMB 3,164 million.

III. Risk Reminder

As required by the relevant laws and regulations in China, the New Drug is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

[1] Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

8 September 2025

* *For identification purposes only*